2024年欧洲肿瘤内科学会亚洲年会（ESMO ASIA）将于当地时间12月6日~8日在新加坡召开。作为专注于亚洲区域多学科肿瘤学的年度盛会，2024 ESMO ASIA将公布多项全球及亚太地区的最新科研和临床进展。目前，大会官网已公布摘要标题，【肿瘤资讯】特对头颈肿瘤领域纳入优选口头报告（Proffered Paper session）专场和迷你口头报告（Mini Oral session）专场摘要进行整理，让我们一睹为快吧。
优选口头报告专场
摘要号：402O
英文标题：Preliminary Results of Phase II Study to Evaluate Safety and Efficacy of Combination Pucotenlimab with Epidermal Growth Factor Receptor-ADC (EGFR-ADC) MRG003 in recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC)
中文标题：Pucotenlimab联合EGFR-ADC MRG003治疗复发或转移性鼻咽癌(R/M-NPC)的安全性和有效性：II期研究初步结
讲者：徐瑞华 中山大学肿瘤防治中心
摘要号：403O
英文标题：Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
中文标题：替雷利珠单抗联合化疗对比安慰剂联合化疗用于复发或转移性鼻咽癌一线治疗：RATIONALE-309研究3年随访结果
讲者：方文峰 中山大学肿瘤防治中心
摘要号：404O
英文标题：A Phase 3 Prospective Randomised Trial Of Two- Weekly TPF(Taxane/Platinum/5FU) vs Three Weekly TPF As Induction Chemotherapy In Locally Advanced Squamous Cell Carcinoma Of Head And Neck- A Preliminary Analysis
中文标题：每2周一次TPF（紫杉醇/铂类/5-FU）对比每3周一次TPF用于局部晚期头颈鳞癌有道化疗：3期前瞻性、随机试验初步分析结果
讲者：Animesh Gupta (Bangalore, IN)
摘要号：405O
英文标题：Accuracy of Plasma Epstein-Barr virus (EBV) DNA for Disease Surveillance in Endemic Nasopharyngeal Carcinoma (NPC):Analysis of a Real-world Database (RWD)
中文标题：血浆Epstein-Barr病毒（EBV）DNA用于鼻咽癌（NPC）疾病监测的准确性：来自真实世界数据库（RWD）分析
讲者：Melvin Lee Kiang Chua (Singapore, SG)
迷你口头报告专场
摘要号：406MO
英文标题：Unique molecular features of Epstein Barr virus-specific cytotoxic T lymphocyte (EBV-CTL) as biomarkers for advanced nasopharyngeal cancer (NPC) patients who received chemotherapy and EBV-CTL
中文标题：Epstein Barr病毒特异性细胞毒性T淋巴细胞（EBV-CTL）作为既往接受化疗和EBV-CTL治疗的晚期鼻咽癌（NPC）患者生物标志物的独特分子特征
讲者：Timothy W. Shuen (Singapore, SG)
摘要号：407MO
英文标题：Capecitabine combined with PD-1 antibody as maintenance therapy after first-line treatment of recurrent or metastatic nasopharyngeal carcinoma: A propensity score matching study
中文标题：卡培他滨联合PD-1单抗用于复发或转移性鼻咽癌一线治疗后维持治疗：倾向评分匹配研究
讲者：Yifu Li (中国广州)
摘要号：LBA3
英文标题：First-line HLX07 vs. Placebo Combined with Serplulimab and Chemotherapy for Nasopharyngeal Cancer: a Randomised, Double-blind, Multicentre Phase 2 study
中文标题：HLX07对比安慰剂联合斯鲁利单抗和化疗一线治疗鼻咽癌：一项随机、双盲、多中心II期临床研究
讲者：张力 中山大学肿瘤防治中心
摘要号：408MO
英文标题：Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
中文标题：确定局部晚期鼻咽癌同步放化疗后辅助化疗的最佳时机
讲者：Hui Chen (中国广州)
摘要号：409MO
英文标题：Induction chemo-immunotherapy with camrelizumab plus modified TPF (nab-paclitaxel, cisplatin, and S1) in locally advanced nasopharyngeal carcinoma: A phase II, single-arm study
中文标题：卡瑞利珠单抗联合改良TPF(白蛋白结合型紫杉醇、顺铂和S1)用于局部晚期鼻咽癌诱导化学免疫治疗：一项II期单臂研究
讲者：吴三纲 厦门大学附属第一医院
摘要号：410MO
英文标题：Pattern and treatment outcomes of second primary cancer (SPC) of the upper aerodigestive tract (UADT) in head and neck squamous cell carcinoma (HNSCC) survivors: A multi-center retrospective cohort study with long-term follow-up
中文标题：头颈鳞癌(HNSCC)幸存者上呼吸消化道(UADT)第二原发癌(SPC)的模式和治疗结局：一项长期随访的多中心回顾性队列研究
讲者：Chak Ki J. Yung (中国香港)
摘要号：411MO
英文标题：Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial
中文标题：Petosemtamab（MCLA-158）单药用于既往经治（2L+）复发/转移性（r/m）头颈鳞癌（HNSCC）：2期临床试验
讲者：Christophe Le Tourneau (Paris, FR)
摘要号：412MO
英文标题：A Real-World Phase IV Superiority Study Among Recurrent or Advanced Head and Neck Cancer Patients Prescribed with Low-Dose Nivolumab and Triple Metronomic Chemotherapy versus Paclitaxel Carboplatin Regimen
中文标题：真实世界IV期优效性研究：低剂量纳武利尤单抗和三联节拍化疗对比紫杉醇卡铂方案治疗复发或晚期头颈肿瘤
讲者：Avinash D. Khadela (Ahmedabad, IN)
摘要号：413MO
英文标题：Impacts of time-of-day of nivolumab infusion on treatment efficacy for patients with head and neck squamous cell carcinoma
中文标题：纳武利尤单抗输注时间对头颈鳞癌患者治疗效果的影响
讲者：Takuro Tsunoki (Gifu, JP)
排版编辑：肿瘤资讯-张薪媛
苏公网安备32059002004080号
